Valuation: Poltreg S.A.

Market Cap 119M 30.2M 27.02M 24.99M 22.63M 42.38M 2.87B 43.05M 301M 1.5B 113M 111M 4.76B P/E 2026 *
-3.65x
P/E 2027 * -1.32x
Enterprise Value 124M 31.47M 28.16M 26.04M 23.58M 44.16M 3B 44.86M 313M 1.57B 118M 116M 4.96B EV / Sales 2026 *
155x
EV / Sales 2027 * 224x
Free-Float
67.57%
Yield 2026 *
-
Yield 2027 * -
1 week+2.81%
Current month-1.95%
1 month-5.63%
3 months-14.10%
6 months+16.86%
Current year-17.96%
1 week 19.35
Extreme 19.35
21.2
1 month 19
Extreme 19
21.7
Current year 16
Extreme 16
28.6
1 year 16
Extreme 16
29.5
3 years 16
Extreme 16
60
5 years 16
Extreme 16
73.9
10 years 16
Extreme 16
73.9
Manager TitleAgeSince
Chief Executive Officer - 30/04/2019
Chief Tech/Sci/R&D Officer - 31/10/2021
Corporate Officer/Principal - 20/02/2024
Director TitleAgeSince
Chairman - 23/05/2021
Director/Board Member 51 20/05/2021
Director/Board Member 43 31/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.81%-23.28%-65.93% 30.26M
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+7.23%+11.14%+74.78% 54.78B
+0.47%+5.10%+8.22%+101.52% 53.49B
-2.06%+2.51%+24.07%+50.98% 45.98B
-1.79%+0.49%+19.32%+122.77% 42.94B
-1.65%+3.34%+237.56%+819.04% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+18.47%+55.14%+45.58% 23.67B
Average +0.56%+2.84%+41.48%+126.93% 38.31B
Weighted average by Cap. +0.12%+2.59%+45.92%+149.86%

Financials

2026 *2027 *
Net sales 800K 203K 182K 168K 152K 285K 19.33M 290K 2.02M 10.12M 762K 746K 32.04M 1M 254K 227K 210K 190K 356K 24.17M 362K 2.53M 12.65M 953K 933K 40.05M
Net income -31M -7.87M -7.04M -6.51M -5.9M -11.05M -749M -11.22M -78.34M -392M -29.53M -28.91M -1.24B -95.7M -24.3M -21.74M -20.11M -18.21M -34.1M -2.31B -34.65M -242M -1.21B -91.18M -89.26M -3.83B
Net Debt 5M 1.27M 1.14M 1.05M 952K 1.78M 121M 1.81M 12.64M 63.26M 4.76M 4.66M 200M 105M 26.66M 23.86M 22.06M 19.98M 37.42M 2.54B 38.01M 265M 1.33B 100M 97.94M 4.21B
Projected Income Statement - Annual - Poltreg S.A.
Logo Poltreg S.A.
Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.
Employees
34
Date Price Change Volume
26/10/26 PLN 20.10 0.00% 1,332
23/10/26 PLN 20.10 -2.43% 111
22/10/26 PLN 20.60 -2.83% 2,659
21/10/26 PLN 21.20 +7.61% 3,644
20/10/26 PLN 19.70 -1.01% 3,398
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
20.10PLN
Average target price
29.30PLN
Spread / Average Target
+45.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Poltreg S.A.